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Letters to the Editorantifungal) and the duration of therapy
(lifelong antibiotic therapy?).
In our opinion, the open questions
remain: (1) Which antibiotic therapy
should be performed in patients with
ABF treated with thoracic endovascu-
lar aneurysm repair? (2) How long
should antibiotic therapy be continued?
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Bozzani and colleagues1 state that
surgical correction of an aortobron-
chial fistula, particularly open cor-
rection of a thoracic aneurysm,
carries a fairly high postoperative
incidence of stent-graft infection.
To the contrary, minimal infection
rates were observed after endovascu-
lar stent placement. The authors
question whether antibiotic therapy
should be administrated after this
minimally invasive operational
procedure.1,2 There is scarce litera-
ture on immunologic consequences
after stent implantation in humans.
According to immunologic data
obtained from patients undergoing
heart operations with cardiopulmo-
nary support and abdominal surgery,
any operation performed in humans
induces a state of immune suppression
in vivo. Therefore, patients undergoing
heart surgery (cardiopulmonary support)512 The Journal of Thoracic and Cshould receive aggressive 5-day antibi-
otic treatment in accordance with the in-
sight of an induced ‘‘systemic immune
suppression’’ after heart surgery.3,4 In
regard to the ongoing discussion of anti-
biotic treatment after endovascular stent
implantation, the following approach
seems to be feasible. Studies have to
be initiated to investigate the immuno-
logic consequence of open and endovas-
cular stent implantation in humans (eg,
abdominal aorta aneurysm repair,
open, closed), and ‘‘yes,’’ antibiotic
treatment should be applied for 4 to 5
days after endovascular stent placement
to potentially ‘‘prohibit’’ pain from in-
fection (local, systemic) in patients.
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TECHNIQUE TO CARBON
DIOXIDE DE-AIRING IN OPEN
CARDIAC OPERATIONS?
To the Editor:
In a recent study Al-Rashidi and as-
sociates1 concluded that ‘‘bilateral .ardiovascular Surgery c February 2010pulmonary collapse and successive
filling of the lungs with . concomi-
tant increase in mechanical ventilation
during de-airing of the left side of the
heart significantly reduces the number
of systemic MES [microembolic sig-
nals]. and. air emboli.’’
Inasmuch as the study’s limitations
were not mentioned, we would like
to discuss a few:
1. Inasmuch as the patients were alter-
nately allotted to control and study
groups, the principle of randomiza-
tion was ignored. Moreover, the
principle of unbiased assessment
was also compromised inasmuch
as the single surgeon, who actively
followed the degree of de-airing via
transesophageal echocardiography
(TEE) during the surgical de-airing
maneuvers before the end of car-
diopulmonary bypass (CPB), thus
participated in the evaluation of
the technique, which he himself
had proposed.
2. The authors enumerate 9 exclusion
criteria, including accidental open-
ing of the pleural cavity and
chronic obstructive lung disease,
although all operations were per-
formed by one highly experienced
surgeon. Consequently, the gener-
alizability of the results cannot but
be very limited.
3. According to the Methods section,
TEE and transcranial Doppler
(TCD) measurements were only
performed after CPB. However, in
the Results section, the authors
make comparisons with the number
of MES before the end of CBP.
Moreover, ‘‘The aortic root was
de-aired’’ before release of the
crossclamp only in the study group.
4. The possible risks of a left ventricu-
lar vent inserted through the apex of
the heart (eg, bleeding and arrhyth-
mias), a prerequisite of the tech-
nique, have not been mentioned.
5. In contrast to common practice as
well as the study group, the con-
trol group patients had their
lungs ventilated continuously during
